Physician Differences in Managing Postmenopausal Osteoporosis
- Barbara LukertAffiliated withDivision of Endocrinology, Metabolism and Genetics, Department of Medicine, University of Kansas Medical Center Email author
- , Sacha Satram-HoangAffiliated withAmgen Inc.
- , Sally WadeAffiliated withWade Outcomes Research and Consulting
- , Mary AnthonyAffiliated withAmgen Inc.
- , Guozhi GaoAffiliated withAmgen Inc.
- , Robert DownsAffiliated withDivision of Endocrinology and Metabolism, Department of Internal Medicine, Virginia Commonwealth University
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Osteoporosis is a disease that often goes undetected until a fracture occurs. Previous reports indicate that disease diagnosis and care of patients with osteoporosis may vary within the medical community.
Objective: Using data from the POSSIBLE US™ registry (October 2004–December 2009), we evaluated patterns of care for a group of primary care (i.e. first-contact) physicians who frequently prescribe osteoporosis medications to determine whether variations existed in the characteristics of their postmenopausal patients; physician approaches to diagnosis; treatment choices and monitoring; and patient-reported medication use.
Methods: POSSIBLE US™ was a large prospective registry of postmenopausal women receiving osteoporosis treatment. We analysed data from 42 family practice physicians (FPPs), 50 internal medicine specialists (IMs) [internists, physicians], 41 gynaecologists (GYNs) and the 4917 patients they enrolled in the POSSIBLE US™ registry between October 2004 and January 2007. Women who had been postmenopausal for at least 1 year and who were newly initiating osteoporosis therapy, switching or augmenting therapy or continuing on a stable therapy regimen were investigated. Therapies included bisphosphonates, full-length or peptide derivative of parathyroid hormone, calcitonin, oral or transdermal postmenopausal estrogen, selective estrogen receptor modulators (SERMs), calcium and/or vitamin D supplements (alone or in combination with other therapies), or any combination of these agents. Data on physician characteristics were collected on an initial qualification questionnaire. Physicians reported data for enrolled patients at study entry and were also asked to provide relevant data obtained at clinic visits throughout the follow-up period. Patient-reported data were collected using questionnaires mailed out semi-annually throughout the follow-up period. Patient-reported and physician-reported data were assessed using ANOVA models and chi-squared (χ2) or Cochran-Mantel-Haenszel tests to evaluate differences across physician types. Multivariate logistic regression models examined the odds of patients having an osteoporosis diagnosis, being prescribed specific agents and receiving an additional dual energy x-ray absorptiometry (DXA) scan after the initial diagnostic scan. Cox proportional hazards regression models were used to determine whether the risk of patient-reported treatment discontinuation during 12 months of follow-up differed by physician characteristics.
Results: Although low-bone density diagnoses were not required, physicians reported DXA as the method of diagnosis in 84% of patients. The majority of patients were prescribed bisphosphonates (55%); the next most frequently prescribed treatment was calcium/vitamin D only (19%). Women treated by GYNs were younger; had fewer co-morbidities, higher T-scores and fewer prior fractures; were 30% less likely to carry a diagnosis of osteoporosis; and were more likely to be treated with SERMs or hormone replacement therapy (HRT) than women treated by IMs or FPPs. Patients cared for by physicians with >30 years of experience were 20% less likely to carry a diagnosis of osteoporosis, had greater odds of receiving either HRT or calcium/vitamin D only and had a higher risk of treatment discontinuation. Overall, there was less laboratory testing to assess secondary causes of osteoporosis in this cohort than might have been expected, given the high incidence of secondary osteoporosis generally in women of similar age.
Conclusions: This study documents potentially important variations in osteoporosis care, even among physicians who frequently prescribe osteoporosis medications.
- Physician Differences in Managing Postmenopausal Osteoporosis
Drugs & Aging
Volume 28, Issue 9 , pp 713-727
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of Endocrinology, Metabolism and Genetics, Department of Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA
- 2. Amgen Inc., Thousand Oaks, CA, USA
- 3. Wade Outcomes Research and Consulting, Salt Lake City, UT, USA
- 4. Division of Endocrinology and Metabolism, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA